Concurrent sequencing of DNA and RNA to detect the predisposition to hereditary cancer.
Skye’s stock sinks following eye disease failure as company shifts focus to obesity
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS